Article info
PDFTherapeutics/Prevention
Randomised controlled trial
Dextromethorphan and quinidine are suitable for off-label short-term treatment of agitation in people with Alzheimer's disease following first-line non-drug approaches
- Correspondence to : Dr Anne Corbett, Wolfson Centre for Age-Related Diseases, King's College London, London SE1 1UL, UK; anne.corbett{at}kcl.ac.uk
Citation
Dextromethorphan and quinidine are suitable for off-label short-term treatment of agitation in people with Alzheimer's disease following first-line non-drug approaches
Publication history
- First published December 23, 2015.
Online issue publication
November 26, 2019
Article Versions
- Previous version (26 November 2019).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/